Anika Therapeutics, Inc. (ANIK) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-29

Key Insights

Two board members (William R. Jellison and Glenn R. Larsen) resigned effective at the 2026 annual meeting, reducing board size from 9 to 7 members; both resignations were non-contentious with no disagreement cited, suggesting planned transitions rather than governance issues.
Q1 2026 financial results were announced on April 29, 2026, with the full press release furnished as an exhibit but not detailed in the 8-K filing itself, limiting immediate visibility into revenue, profitability, or guidance changes.
The company maintains its listing on NASDAQ Global Select Market and is not classified as an emerging growth company, indicating it is a mature public company with established reporting obligations and institutional investor base.

Want the newest filings?

This analysis covers the filing from 2026-04-29. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-26

Anika Therapeutics reported its Q4 2025 and full-year 2025 financial results, which investors will want to review closely for signs of revenue growth, margin changes, and guidance updates.
The company announced that its Executive Vice President, General Counsel and Corporate Secretary, David Colleran, will be transitioning out of his role by May 1, 2026, which could signal leadership changes.
Investors should review the details of the Transitional Services and General Release of Claims Agreement between the company and Mr. Colleran to understand the terms of his departure.

Filed: 2026-01-08

Anika Therapeutics has reaffirmed its 2025 revenue guidance, with the commercial channel expected to grow 12-18% year-over-year and the OEM channel to decline 16-20% year-over-year.
The company is undergoing a leadership transition, with CEO Cheryl R. Blanchard stepping down and being replaced by Steve Griffin as the new President and CEO effective February 1, 2026.
As part of the transition, Blanchard will take on the role of Executive Chair of the Board for 12 months, followed by a 6-month period as a Special Advisor, before remaining as an employee for an additional 6 months.

Other reports for Anika Therapeutics, Inc.

Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.